rafamin
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
6
Phase 4
0
Earliest trial started Apr 29, 2021 (NCT04918771)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Mycobacterium tuberculosisINHIBITOR
Mycobacterium tuberculosis inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06901297 | Phase 3 | Apr 3, 2025 | Materia Medica Holding |
| NCT06715891 | Phase 3 | Sep 29, 2024 | Materia Medica Holding |
| NCT06263881 | Phase 3 | Dec 1, 2023 | Materia Medica Holding |
| NCT06284265 | Phase 3 | Oct 16, 2023 | Materia Medica Holding |
| NCT05364671 | Phase 3 | Apr 29, 2022 | Materia Medica Holding |
| NCT04918771 | Phase 3 | Apr 29, 2021 | Materia Medica Holding |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Materia Medica Holding | For profit | 6 | 6 | 1 | 2021 |
1 organizations
Page 1 / 1